ロード中...
Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate
Dimethyl fumarate (DMF) is the most recent oral disease-modifying therapy approved by the US Food and Drug Administration and is indicated for the treatment of relapsing forms of multiple sclerosis (MS). Prior to approval for use in MS, DMF and its active metabolite, monomethyl fumarate, had been us...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4094574/ https://ncbi.nlm.nih.gov/pubmed/25045248 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S50962 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|